Invivyd, Inc. (Nasdaq: IVVD) Earnings Report Highlights

• Invivyd, Inc. reported a Q4 2025 revenue of $17.2 million, surpassing estimates and indicating strong demand for PEMGARDA.
• The company's cash and cash equivalents stood at $226.7 million by the end of 2025, bolstered by significant financing activities.
• Invivyd is advancing its DECLARATION Phase 3 clinical trial for VYD2311, with Fast Track designation from the FDA and expected top-line data by mid-2026.

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company focused on developing treatments for serious viral infectious diseases, notably SARS-CoV-2, through a proprietary technology platform. On March 5, 2026, IVVD reported its earnings, revealing an earnings per share (EPS) of -$0.064, slightly below the estimated EPS of -$0.06. Despite this, the company generated a revenue of $17.2 million, surpassing the estimated revenue of $15.5 million.

The revenue of $17.2 million for Q4 2025 was driven by sales of PEMGARDA (pemivibart), marking a 25% increase year-over-year and a 31% increase quarter-over-quarter. This growth indicates strong demand for the product. By the end of 2025, Invivyd had cash and cash equivalents totaling $226.7 million, supported by over $200 million raised through financing transactions in the latter half of the year.

In addition to its financial performance, Invivyd is advancing its DECLARATION Phase 3 pivotal clinical trial for VYD2311, a vaccine-alternative antibody aimed at preventing COVID-19. The trial has received Fast Track designation from the FDA, with top-line data expected by mid-2026. The trial has reached full enrollment, and the Independent Data Monitoring Committee (IDMC) has recommended the inclusion of pregnant and breastfeeding women.

Financially, IVVD has a price-to-earnings (P/E) ratio of approximately -5.61, indicating negative earnings. Its price-to-sales ratio is about 4.25, suggesting investors are willing to pay $4.25 for every dollar of sales. The enterprise value to sales ratio is low at 0.052, which may imply undervaluation relative to its sales. Despite challenges in generating positive cash flow, the company maintains a strong equity position with a debt-to-equity ratio of 0.010 and a robust current ratio of 7.24.